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We describe the case of a 55-year-old man with a biological prosthetic aortic valve who suﬀered from epigastrium and
right hypochondrium pain associated with intermittent night sweats. Liver biopsy showed infectious hepatitis pattern without
pathognomonic features. Coxiella burnetii serology was suggestive of chronic Q fever, and modified Duke’s criteria for endocarditis
were also fulfilled. The authors present a brief literature review concerning chronic Q fever, emphasizing absent previous reports
of chronic Q fever with hepatitis and endocarditis and no increase in inflammatory markers.
1. Introduction
Q fever is a worldwide zoonosis caused by the “rare and
fastidious bacteria” [1] Coxiella burnetii (C. burnetii). Its
incidence is unknown and may be underestimated [2].
Clinical and laboratory presentation can be polymorphic,
nonspecific and represents a great challenge for clinicians.
Left untreated chronic Q fever is a potential lethal condition
[1].
2. Case Presentation
A 55-year-old man, lawyer, was admitted to the hospital
because of abdominal pain located in the epigastrium
and right hypochondrium, intermittent night sweats, and
3 kg involuntary weight loss over the preceding 8 months.
Approximately 5 years earlier severe aortic valve stenosis,
with left ventricular hypertrophy, paroxysmal atrial fibrilla-
tion, and heart failure (class III NYHA) were diagnosed, and
aortic valve replacement was performed using a biological
prosthetic valve. Furthermore, the patient was an alcohol
user (70 g/day) and had endoscopically diagnosed chronic
antral gastritis. He lived in an urban area but, approximately
18 months before admission, he traveled to Nepal living
in settings with poor hygienic standards. Daily medications
included omeprazole 20mg.
Approximately one year before admission, the patient
began to have intermittent, profuse night sweats associ-
ated with abdominal pain located in the epigastrium, and
right hypochondrium. He reported no fever or chills. No
remarks on routine physical examination performed by his
attending physician were made, and Table 1 summarizes
the results of prescribed laboratory tests. Serologies for
human immunodeficiency virus (HIV), hepatitis B virus
(HBV), hepatitis C virus (HCV), and VDRL were negative.
Serologies for cytomegalovirus (CMV) and Epstein Barr
virus (EBV) showed past infections. Two blood cultures
were negative. A transthoracic echocardiography detected
hemodynamically well-functioning aortic valve prosthesis,
ascendant aortic dilatation, and no valve vegetations. An
abdominal ultrasound revealed a biliary cyst of the liver.
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Table 1: Laboratory tests.
Normal range
1 year before
admission
4 months before
admission
On admission
After 1 month of
treatment
Hemoglobin (g/dL) 13.5–17.5 14.4 14 12.8 13.7
MCV (fL) 78–96 82.5 82.3 78.8 83.4
MCH (pg) 26–33 27.6 27.7 25.7 27.5
White-cell count (per mm3) 4,500–11,000 7,380 7,210 9,090 7,100
Platelet count (per mm3) 150,000–450,000 220,000 185,000 139,000 177,000
ALP (U/L) 30–120 112 106 110 103
AST (U/L) <50 48 43 61 31
ALT (U/L) <50 53 36 73 35
LDH (U/L) <240 206 234 218
ESR (mm/h) <20 13 15 2
CRP (mg/L) <5.0 2.2 5.0 4.1 3.2
Ferritin (ng/mL) 24–336 298 418 193
His physician eventually decided to prescribe sertraline for
depression.
Four months before admission, the patient was still
complaining of abdominal pain, with the same characteris-
tics and was referred to our out-patient clinic. Laboratory
tests were repeated (Table 1), protein electrophoresis was
performed, and results were within normal range.
Meanwhile, during a work trip to Brazil, the patient
developed lower limbs leukocytoclastic vasculitis (Figure 1).
Due to worsening of intermittent night sweats, persis-
tence of abdominal pain, and 3 kg involuntary weight loss
over the preceding 8 months with no fever, the patient was
admitted to the hospital.
On examination, the patient was in good condition, the
temperature was 37.1◦C, the pulse rate 75 beats per minute,
the blood pressure was 130/75mmHg, and respiratory rate
was 15 per minute. The oxygen saturation in ambient air was
98%, good oral and dental health. There was no superficial
lymphadenopathy. There was no jugular venous distension.
Auscultation of the heart revealed a mechanical second heart
sound, a grade II/VI systolic murmur in the aortic area.
No chest rales were detected. There were no conjunctival
hemorrhages, Osler’s nodes, Janeway’s lesions, Roth’s spots,
splinter hemorrhages, or peripheral edema.
The electrocardiogram showed a normal sinus rhythm
with nonspecific repolarization abnormalities.
Routine laboratory tests (Table 1) were performed and
revealed hemoglobin 12.8 g/L [13.5–17.5], platelet count
139,000 per mm3 [150,000–450,000], aspartate amino-
transferase (AST) 61U/L [<50U/L], alanine aminotrans-
ferase (ALT) 73 [<50U/L], alkaline phosphatase (ALP)
110 [<120U/L], ferritin 418 ng/mL [24–336], C-reactive
protein (CRP) 4.1 [<5.0mg/L], erythrocyte sedimentation
rate (ESR) 15mm/hr [<20], and rheumatoid factor (RF)
318U/mL [<14]. Electrolyte panel and urinalyses were nor-
mal. Serologies for HIV, HBV, HCV, Schistosoma, Borrelia,
Rickettsia, Leishmania, and VDRL were negative. Serologies
for CMV, EBV, and Toxoplasmose showed past infections.
Figure 1: Skin biopsy. Perivascular dermatitis with purpura
(arrows).
Widal andHuddlesson reactions and research of Plasmodium
sppwere negative as well. Two sets of blood culture speci-
mens exhibited no growth. Protein electrophoresis showed
IgG-K/λmonoclonal hypergammaglobulinemia. Abdominal
ultrasound detected mild hepatosplenomegaly. Thoracic-
abdominal-pelvic computer tomography disclosed gastric
wall calcification and confirmed hepatosplenomegaly. To
rule out endocarditis, transesophageal echocardiography was
performed. Two very small echodense images suggestive of
surgery-related alterations versus fibrosis were detected on
the aortic cups (Figures 2(a) and 2(b)). Fundus examination
showed no retinal abnormalities.
Liver biopsy revealed infectious hepatitis without
pathognomonic features (Figure 3) and with no fibrin ring
granulomas described in Q fever.
EDTA-whole blood and paraﬃn-included liver biopsy
were then sent to CEVDI/INSA for C. burnetii laboratory
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Figure 2: Transesophageal echocardiography. Echodense images on the aortic cups indicated by arrows. Left atrium (LA), left ventricle (LV),
aorta (Ao).
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Figure 3: Liver biopsy. polymorphic inflammatory infiltrate of
the portal spaces with extravasation into the hepatic parenchyma
(black arrows), cell aggregates outlining granulomas (red star), focal
necrosis of hepatocytes (black star).
diagnosis. The serologic evaluation was performed by Indi-
rect Immunofluorescence Assay (IFA) using the commercial
C. burnetii I+II IgG/A/M Immunofluorescence kit (Vircell
Microbiologists, Granada, Spain). It revealed a high anti-
phase I IgG with an end-point titer of 204,800 suggestive of
chronic Q fever (anti-phase I IgG ≥800 was the reference
cut-oﬀ, Table 2 for results). C. burnetii active infection
was also confirmed by molecular testing. For this purpose,
genomic DNA was extracted from buﬀy coat and liver tissue
using DNeasy blood & tissue kit (Qiagen GmbH, Hilden,
Germany). The presence of C. burnetii DNA was screened
by polymerase chain reaction (PCR) in a nested reaction
using the primers pairs Trans1-Trans2 and Trans3-Trans4
that target a transposon-like repetitive region in the agents
genome [3]. Specific DNA was detected in liver tissue but
not in blood, and C. burnetii identity was confirmed by
amplicon sequencing. The quality of DNA in both samples
was previously verified by amplification of human β-actin
gene as internal control. Moreover, the absence of bacteria
in blood sample was reinforced by a negative result also
obtained for the isolation attempt. In fact, an additional buﬀy
coat aliquot was inoculated in DH82 cells, routinely used in
CEVDI for C. burnetii isolation, and after a standard 60-
day incubation at 37◦C and 5% CO2 atmosphere in BSL3
condition, no bacteria growth could be detected. The paraﬃn
processing of the liver sample limited its utility for agents
isolation.
Final diagnosis of chronic Q fever was made, with his-
tologically documented infectious hepatitis and endocarditis
by modified Duke’s criteria [4]. Our patient met one of the
major criterion of Q fever endocarditis (C. burnetii serology
with anti-phase I IgG titer >800) and three minor criteria
(predisposing heart condition with biological prosthetic
aortic valve, immunological phenomena with RF positive,
vascular phenomena with leukocytoclastic vasculitis). Fur-
thermore, we probably may consider the valvular alterations
detected by transesophageal echocardiography as a minor
criterion (echocardiographic findings not meeting a major
criterion).
Antimicrobial therapy with doxycycline 100mg bid, and
hydroxychloroquine 200mg tid was started and the patient
became asymptomatic within 8 days.
The patient is still being followed in our out-patient clinic
and he is adhering to treatment. He remains well and his
weight gradually returned to normal (75 kg-BodeMass Index
23,1), 8 months after the diagnosis. The titers of antibodies
toC. burnetii have been falling in response to therapy. Results
of the periodical serological tests are summarized in Table 2,
together with results of the laboratory tests (Table 1).
3. Discussion
C. burnetii is a short and pleomorphic, strictly intracellular,
gram negative coccobacillus with high resistance to chemical
and physical agents as well as to antimicrobial therapy [5].
Humans are exposed to the disease through contact with
animal hosts, such as, humans, ruminants (cattle, sheep,
goats), pets, and rarely wild animals. Infection is manly
acquired by the respiratory or digestive route [6].
Q fever may be acute or chronic. Acute infection can
cause symptoms ranging from a flu-like illness to severe
presentations like pneumonia and hepatitis. Only 1 to
5% of patients progress to chronic infection. This may
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Table 2: C. burnetii titers (IFA).
On admission After 1 month of treatment After 2 months of treatment After 6 months of treatment
Phase I IgM 200 50 50 <50
Phase I IgA 800 100 100 100
Phase I IgG 204,800 204,800 102,400 102,400
Phase II IgM 200 50 50 <50
Phase II IgA <50 <50 <50 <50
Phase II IgG 204,800 409,600 204,800 51,200
develop insidiously months to years after the acute disease
and the diagnosis is often delayed 12 to 24 months [7].
The most frequent and serious chronic presentation of
Q fever is endocarditis. Less commonly, the disease may
cause osteoarticular infections, vascular infections including
infection of grafts, granulomatous hepatitis and chronic
hepatitis, chronic pulmonary infection, and infection during
pregnancy [5]. Chronic Q fever most often aﬀects adult
males, professionally exposed, with preexistent cardiovascu-
lar disease (valve lesion, valvular prosthesis, vascular graft),
immunocompromised, living in rural areas, or who had
shorts exposures, such as, farm visits or travels [2]. It should
be considered for all patients with a heart valve lesion who
present fever and negative blood cultures [1].
We believe that our patient could have been infected in
Nepal although C. burnetii is endemic in Portugal as well.
The patient reported that he had contacts with farm animals
and he most likely consumed unpasteurized dairy products.
Clinical manifestations of chronic Q fever vary widely,
with low-grade fever and acute heart failure as the most
common observed signs. Constitutional symptoms including
anorexia, weakness, malaise, fatigue, anorexia, as in our
patient, night sweats, and weight loss can also be present.
Hepatosplenomegaly and purpuric rash due to circulating
immune complexes are described as well [8]. Laboratory
manifestations are typical of the cell-mediated inflammatory
response [9]. Hematological abnormalities include mild
elevation of both transaminases and alkaline phosphatase.
Elevated ESR and hypergammaglobulinemy are seen in most
patients, with significant increase in those diagnosed at a
mean of 18 months [10]. Our patient suﬀered from a rare
case of chronic Q fever with endocarditis and hepatitis with
no increased inflammatory markers.
Serology is the most used diagnostic method for Q fever.
During acute infection, antibodies to phase II antigens are
detected first, whereas persisting high levels of antibodies to
phase I antigens are indicative of chronic Q fever infection.
Chronic Q fever is suspected if titers of phase I IgG antibodies
are >800 [2]. PCR assay is a method that could be used for
the diagnosis of chronic Q fever but its eﬃciency is reduced
in the serum samples due to small amount of bacterial DNA
and elevated C. burnetii antibodies titer present [11]. Other
diagnostic techniques include demonstration of C. burnetii
in the tissues or isolation of C. burnetii in cells culture.
Our patient’s liver biopsy showed no fibrin-ring granu-
lomas. This finding is consistent with literature because this
type of granulomas has never been observed in the liver of
patients with endocarditis [12].
Echocardiography, even if transesophageal, has signifi-
cant limitations in diagnosing Q fever endocarditis due to
the small size and nodular shape of the vegetations. Valvular
abnormalities more frequently described are fibrosis and
calcification [13]. In our case, valvular findings visualized
by transesophageal echocardiography were not considered,
at the beginning, suggestive of endocarditis vegetations.
The combination of doxycycline with hydroxychloro-
quine for at least 18 months is the more eﬀective therapy for
chronic Q fever [8, 14].
Surgical valve replacement is generally indicated for
hemodynamic reasons after at least 3 weeks of antimicrobial
treatment [15].
Apyrexia within 7 days is the clinical expected response.
Hepatomegaly and splenomegaly disappear within 2 to 12
weeks, and biochemical tests slowly return to normal.
During therapy serological testing and transesophageal
echocardiography should be performed because of the
possibility of later relapse, together with ophthalmologic
examination aimed at monitoring toxicity from hydroxy-
chloroquine [6].
In conclusion, we described a case of chronic Q fever
with hepatitis and endocarditis that should help clinicians to
consider this diagnosis, performing systematically C. burnetii
serology, for all patients with heart valve lesions who present
with nonspecific symptoms, even if they are apyretic and
exhibit no elevation of inflammatory markers.
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